tiprankstipranks
Trending News
More News >
NEXUS AG (DE:NXU)
XETRA:NXU
Advertisement

NEXUS AG (NXU) AI Stock Analysis

Compare
13 Followers

Top Page

DE:NXU

NEXUS AG

(XETRA:NXU)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
€78.00
▲(8.48% Upside)
NEXUS AG's overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and robust profitability metrics. However, the stock's valuation appears high, and technical indicators suggest a lack of momentum, which tempers the overall score.

NEXUS AG (NXU) vs. iShares MSCI Germany ETF (EWG)

NEXUS AG Business Overview & Revenue Model

Company DescriptionNexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and KIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/REHAB for rehabilitation facilities; ITR, a software for rehabilitation, clinics, and hotels with medical care; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/QM for quality management; NEXUS/INTEGRATION SERVER, an interface management; NEXUS/CLOUD IT, outsourcing solution; NEXUS/EPS, a software solution to supplement SAP personnel management, as well as process and HR consulting in the SAP environment; ifa systems, an ophthalmology software solution; Sophrona solutions, ophthalmology patients and referral program; and NEXUS/DIS, interdisciplinary diagnostic information system. Its information systems also comprise NEXUS/SWISSLAB, a laboratory information system; NEXUS/LAURIS for order communication in diagnostics; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; dc-Pathos and dc-LabMan for pathology and cytology devices; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUs/CHILI, for PACS and teleradiology solutions; NEXUS/ASTRAIA for obstetrics and gynecology; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical specialist diagnostics and device integration; NEXUS/HOME for senior citizen and nursing homes; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/PAT, an administration system for hospitals; and osoTEC for billing personal and other services. In addition, the company offers SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS/EPD, NEXUS/AEMP, NEXUS/SPM, EuroSDS, RVS Software, NEXUS/VITA and TESIS VITA, and NEXUS/ESKULAP. NEXUS AG is headquartered in Donaueschingen, Germany.
How the Company Makes MoneyNEXUS AG generates revenue through a diversified business model that includes software licensing, subscription services, and professional consulting. The primary revenue stream comes from the sale of software licenses for its ERP and CRM solutions, which often involve one-time fees and ongoing maintenance contracts. Additionally, the company offers subscription-based cloud services that provide clients with access to its software on a recurring basis, ensuring a steady income flow. Professional services, including implementation, training, and support, also contribute significantly to revenue. Key partnerships with cloud service providers and technology firms enhance NEXUS AG's market reach and capabilities, enabling access to a broader customer base and facilitating co-development of innovative solutions that drive additional revenue opportunities.

NEXUS AG Financial Statement Overview

Summary
NEXUS AG demonstrates a solid financial position with consistent revenue growth and strong profitability metrics. The low leverage and high equity ratio enhance financial stability. While cash flow metrics are positive, there is potential for further improvement in cash conversion efficiency.
Income Statement
78
Positive
NEXUS AG shows a strong financial performance with consistent revenue growth, achieving a 2.26% increase in TTM. The company maintains healthy profit margins, with a TTM net profit margin of 12.10% and an EBIT margin of 16.92%. However, the gross profit margin has decreased compared to previous years, indicating potential cost management challenges.
Balance Sheet
82
Very Positive
The balance sheet is robust with a low debt-to-equity ratio of 0.072, indicating low leverage and financial stability. The return on equity is solid at 11.91%, reflecting efficient use of equity to generate profits. The equity ratio stands at 61.48%, showcasing a strong equity base relative to total assets.
Cash Flow
75
Positive
Cash flow performance is positive, with a 3.41% growth in free cash flow in TTM. The operating cash flow to net income ratio is 0.51, indicating good cash conversion. However, the free cash flow to net income ratio of 0.83 suggests room for improvement in converting profits into free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue274.56M261.46M241.46M209.13M188.18M162.94M
Gross Profit194.82M223.09M65.97M176.46M159.09M141.60M
EBITDA67.04M61.43M53.43M44.81M40.76M36.69M
Net Income34.21M30.82M24.03M19.35M17.15M14.92M
Balance Sheet
Total Assets478.19M437.73M411.72M344.20M247.34M223.16M
Cash, Cash Equivalents and Short-Term Investments144.12M117.23M99.00M110.46M26.30M26.45M
Total Debt19.98M20.91M20.25M18.67M16.63M13.15M
Total Liabilities180.79M154.77M153.13M105.25M104.94M99.58M
Stockholders Equity293.93M279.24M255.09M235.03M138.79M120.20M
Cash Flow
Free Cash Flow51.51M41.15M20.95M28.30M25.82M25.60M
Operating Cash Flow61.02M51.54M30.41M33.88M31.39M30.95M
Investing Cash Flow-12.62M-30.32M-17.02M-98.55M-21.25M-22.00M
Financing Cash Flow-12.91M-19.63M-16.72M57.97M-11.08M-16.14M

NEXUS AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price71.90
Price Trends
50DMA
71.08
Positive
100DMA
71.23
Positive
200DMA
70.13
Positive
Market Momentum
MACD
0.11
Negative
RSI
59.16
Neutral
STOCH
72.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:NXU, the sentiment is Positive. The current price of 71.9 is above the 20-day moving average (MA) of 71.17, above the 50-day MA of 71.08, and above the 200-day MA of 70.13, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.16 is Neutral, neither overbought nor oversold. The STOCH value of 72.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:NXU.

NEXUS AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
45.86M10.663.77%-5.72%-25.19%
68
Neutral
€1.24B36.2412.38%0.32%6.72%33.84%
67
Neutral
1.26B67.465.34%0.21%1.16%-43.53%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:NXU
NEXUS AG
71.90
16.58
29.96%
GB:0MSD
CompuGroup Medical
24.20
10.00
70.42%
GB:0HI7
MeVis Medical Solutions
25.60
0.00
0.00%

NEXUS AG Corporate Events

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Sep 15, 2025

NEXUS AG, a company involved in a share buy-back program, announced that no shares were repurchased between September 8 and September 12, 2025. The company has previously disclosed the start of this program on July 24, 2023, and has repurchased a total of 63,432 shares to date. These transactions are conducted through a credit institution on the Frankfurt Stock Exchange’s electronic trading platform, Xetra.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR76.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Sep 1, 2025

NEXUS AG, a company involved in the healthcare software industry, announced that no shares were bought back from August 25 to August 29, 2025, as part of their ongoing share buy-back program initiated on July 24, 2023. The total volume of shares repurchased under this program amounts to 63,432 shares, with transactions conducted exclusively on the Frankfurt Stock Exchange’s electronic platform, Xetra, by a commissioned credit institution.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR78.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Aug 25, 2025

NEXUS AG, a company involved in a share buy-back program, announced that no shares were repurchased between August 18, 2025, and August 22, 2025. The program, which began on July 24, 2023, has so far resulted in the repurchase of 63,432 shares, with transactions conducted exclusively on the Frankfurt Stock Exchange’s electronic platform, Xetra.

The most recent analyst rating on (DE:NXU) stock is a Buy with a EUR79.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Aug 18, 2025

NEXUS AG, a company involved in capital market activities, announced that during the period from August 11 to August 15, 2025, no shares were repurchased under its share buy-back program initiated on July 24, 2023. The total volume of shares repurchased under this program amounts to 63,432 shares, with transactions conducted exclusively on the Frankfurt Stock Exchange’s electronic trading platform, Xetra. This announcement highlights the company’s ongoing efforts in managing its capital structure, which could influence investor perceptions and market dynamics.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Delistings and Listing ChangesShareholder Meetings
Nexus AG Faces Squeeze-Out Demand from Project Neptune Bidco GmbH
Neutral
Aug 11, 2025

Nexus AG has received a specified squeeze-out demand from Project Neptune Bidco GmbH, a holding company managed by affiliates of TA Associates Management, L.P. This demand involves the transfer of all shares held by minority shareholders to Project Neptune Bidco GmbH, the majority shareholder, with a cash compensation set at EUR 70.00 per share. The squeeze-out will be effective upon approval at the general meeting scheduled for 25 September 2025 and subsequent registration in the commercial register.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-back Program
Neutral
Aug 11, 2025

NEXUS AG, a company involved in a share buy-back program, announced that no shares were repurchased between August 4 and August 8, 2025. The program, which started on July 24, 2023, has so far resulted in the buyback of 63,432 shares. The repurchases are conducted through a credit institution on the Frankfurt Stock Exchange’s electronic trading platform, Xetra. This activity is part of NEXUS AG’s ongoing efforts to manage its share capital and potentially enhance shareholder value.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Aug 4, 2025

NEXUS AG, a company involved in a share buy-back program, announced that no shares were repurchased between July 28 and August 1, 2025, as part of its 2023 initiative. The total number of shares bought back so far is 63,432, with transactions conducted via the Frankfurt Stock Exchange’s Xetra platform by a commissioned credit institution.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Jul 28, 2025

NEXUS AG, a company involved in the capital market, has announced that no shares were bought back between July 21 and July 25, 2025, as part of its share buy-back program initiated in 2023. The total volume of shares repurchased under this program amounts to 63,432 shares, with transactions conducted exclusively on the Frankfurt Stock Exchange’s Xetra platform.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Updates on Share Buy-Back Program
Neutral
Jul 21, 2025

NEXUS AG, a company engaged in a share buy-back program, announced that no shares were repurchased between July 14 and July 18, 2025, as part of their 2023 initiative. The company has so far repurchased a total of 63,432 shares through a credit institution on the Frankfurt Stock Exchange’s Xetra platform, highlighting their ongoing commitment to this financial strategy.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Stock Buyback
NEXUS AG Reports No Share Buybacks in Recent Period
Neutral
Jul 14, 2025

NEXUS AG announced that during the period from July 7 to July 11, 2025, no shares were repurchased as part of its share buy-back program, which began on July 24, 2023. The total volume of shares bought back under this program amounts to 63,432 shares. The repurchase transactions are conducted through the Frankfurt Stock Exchange (Xetra) by a commissioned credit institution.

The most recent analyst rating on (DE:NXU) stock is a Hold with a EUR70.00 price target. To see the full list of analyst forecasts on NEXUS AG stock, see the DE:NXU Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025